🔗 Share this article The Global Health Body Raises Alert Over Severe Lack of Obesity Jabs Fewer than 10% of individuals eligible to benefit from weight-loss injections including Wegovy have access to them, warns the World Health Organization as it publishes its first advice on the therapies. Given over a billion individuals worldwide currently obese, it is advocating for more widespread and fairer availability to these injectable treatments. According to forecasts, in excess of 2,000,000,000 could be obese by 2030 without intervention. "The new guidelines affirms that obesity is a long-term condition that can be treated with thorough and ongoing care," stated WHO director-general Tedros Adhanom Ghebreyesus. High costs, insufficient output, and supply-chain constraints are key hurdles to widespread availability to the treatments that can aid individuals in losing significant body mass, notes the body. GLP-1 Therapy Supply Crisis Even under the current most favorable outlook, the production of such drugs might only reach around 100 million people – fewer than 10% of eligible patients, per the WHO. The recommendation calls on nations and manufacturers to increase availability, via measures such as patent sharing. The intellectual property rights on the active ingredient – the primary ingredient of Novo Nordisk's Wegovy – is set to lapse in multiple countries in 2026. How Obesity Jabs Operate GLP-1 drugs mimick a body's own hormone to delay gastric emptying, curb appetite and increase the sense of being full so people eat less. Patients commonly start to lose weight within a few weeks of beginning the regular doses. Evidence points to patients may regain a significant portion within a year of discontinuing the medication, because their normal food cravings come back. Being overweight or obese raises your chance for developing medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and certain malignancies. Obesity affects people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, according to the health agency.
Fewer than 10% of individuals eligible to benefit from weight-loss injections including Wegovy have access to them, warns the World Health Organization as it publishes its first advice on the therapies. Given over a billion individuals worldwide currently obese, it is advocating for more widespread and fairer availability to these injectable treatments. According to forecasts, in excess of 2,000,000,000 could be obese by 2030 without intervention. "The new guidelines affirms that obesity is a long-term condition that can be treated with thorough and ongoing care," stated WHO director-general Tedros Adhanom Ghebreyesus. High costs, insufficient output, and supply-chain constraints are key hurdles to widespread availability to the treatments that can aid individuals in losing significant body mass, notes the body. GLP-1 Therapy Supply Crisis Even under the current most favorable outlook, the production of such drugs might only reach around 100 million people – fewer than 10% of eligible patients, per the WHO. The recommendation calls on nations and manufacturers to increase availability, via measures such as patent sharing. The intellectual property rights on the active ingredient – the primary ingredient of Novo Nordisk's Wegovy – is set to lapse in multiple countries in 2026. How Obesity Jabs Operate GLP-1 drugs mimick a body's own hormone to delay gastric emptying, curb appetite and increase the sense of being full so people eat less. Patients commonly start to lose weight within a few weeks of beginning the regular doses. Evidence points to patients may regain a significant portion within a year of discontinuing the medication, because their normal food cravings come back. Being overweight or obese raises your chance for developing medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and certain malignancies. Obesity affects people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, according to the health agency.